CASE REPORT

Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilemma

Blaire Anderson1, Jordan Nostedt1, Safwat Girgis2, Tara Dixon2, Veena Agrawal3, Edward Wiebe4, Peter A. Senior3, and A.M. James Shapiro1,3,*

1Department of Surgery, University of Alberta, Edmonton, Canada, 2Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada, 3Department of Medicine, Division of Endocrinology and Metabolism, University of Alberta, Edmonton, Canada, and 4Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Canada

*Correspondence address. Canada Research Chair in Transplantation Surgery and Regenerative Medicine, University of Alberta, 2000 College Plaza, 8215 112th St., Edmonton, AB, Canada T6G 2C8. Tel: +1-780-4077330; Fax: +1-780-4078259; E-mail: amjs@islet.ca

Abstract

Insulinoma is the most common cause of endogenous hyperinsulinemic hypoglycemia in adults. An alternate etiology, non-insulinoma pancreatogenous hypoglycemia (NIPH), is rare. Clinically, NIPH is characterized by postprandial hyperinsulinemic hypoglycemia, negative 72-h fasts, negative preoperative localization studies for insulinoma and positive selective arterial calcium infusion tests. Histologically, diffuse islet hyperplasia with increased number and size of islet cells is present and confirms the diagnosis. Differentiating NIPH from occult insulinoma preoperatively is challenging. Partial pancreatectomy is the procedure of choice; however, recurrence of symptoms, although less debilitating, occurs commonly. Medical management with diazoxide, verapamil and octreotide can be used for persistent symptoms. Ultimately, near-total or total pancreatectomy may be necessary. We report a case of a 67-year-old male with hypoglycemia in whom preoperative workup, including computerized tomography abdomen, suggested insulinoma, but whose final diagnosis on pathology was NIPH instead.

INTRODUCTION

Endogenous hyperinsulinemic hypoglycemia in adults is most commonly secondary to insulinoma islet cell tumors. These tumors are characterized by Whipple’s triad of hypoglycemia after fast or exercise, neuroglycopenic symptoms and immediate relief with oral or intravenous glucose administration. A monitored fast with documented hypoglycemia accompanied by symptoms, elevated insulin, C-peptide and proinsulin together confirm the presence of endogenous hyperinsulinemic hypoglycemia [1]. Exogenous hyperinsulinemic hypoglycemia (factitious hypoglycemia), characterized by undetectable proinsulin and C-peptide levels, should be excluded. Urinary or plasma sulfonylureas should also be assessed to rule out surreptitious sulfonylurea ingestion.

Non-insulinoma pancreatogenous hypoglycemia (NIPH) or adult-onset nesidioblastosis, defined as diffuse proliferation of pancreatic islet cells, is a rare cause of hyperinsulinemic hypoglycemia representing only 0.5–5% of such cases [2]. The majority of cases reported in adults occur following bariatric surgery and are thought to be secondary to elevated
glucagon-like peptide-1 causing pancreatic islet cell hyperplasia [3–5]. Postprandial hyperinsulinemic hypoglycemia, negative 72-h fasts, negative preoperative localization studies for insulinoma and positive selective arterial calcium infusion tests together are suggestive; however, differentiating insulinoma and NIPH preoperatively remains challenging and ultimately requires histologic assessment.

CASE REPORT

A 67-year-old male retired biochemistry professor presented to the emergency department with a recent history of falls and decreased level of consciousness. He was found to be profoundly hypoglycemic with no antecedent history. Medical history was notable for hypertension, chronic obstructive pulmonary disease, transient complete heart block with bradycardia, alcohol abuse and Wernicke–Korsakoff syndrome. There was no history of surgical intervention, notably no bariatric or gastric procedures. Physical examination was unremarkable.

The patient was investigated for hypoglycemia. His serum glucose could only be maintained with continual intravenous infusion of 40% dextrose, subcutaneous octreotide and oral dextrose tablets. Laboratory investigations revealed inappropriately elevated C-peptide and insulin levels in the context of extreme hypoglycemia and negative sulfonylurea screen, suggestive of insulinoma (Fig. 1). Imaging of the abdomen demonstrated a 2.2-cm arterial enhancing mass in the tail of the pancreas, felt to be consistent with a neuroendocrine tumor (Fig. 2). No evidence of multifocal or metastatic disease was present on further workup including computerized tomography (CT) of the chest and positron emission tomography (PET) CT.

Based on sustained hypoglycemia, inappropriate insulin and C-peptide secretion on repeated measures, and the presence of the arterially enhancing mass in the pancreatic tail, a decision was made to proceed with distal pancreatectomy and splenectomy. Intraoperatively, a mass corresponding with preoperative imaging was appreciated. Laparotomy revealed no evidence of other intraabdominal macroscopic disease. Intraoperative ultrasound was considered but not readily available as surgery was carried out in emergency evening hours.

Postoperatively, the patient had persistent hypoglycemia and neuroglycopenia. His pre-existing cognitive issues led to variable oral intake; therefore, ultimately he was stabilized with supplementary nasogastric tube feeds, but ongoing hypoglycemia necessitated diazoxide and acarbose. Additional investigations, including octreotide scan and endoscopic ultrasound of the pancreas, did not show signs of multifocal or metastatic disease.

Surprisingly, final pathology revealed no evidence of a discrete neuroendocrine lesion, despite preoperative imaging findings and a grossly palpable lesion at surgery. Histologically, a pattern consistent with diffuse beta islet cell disorder, i.e. NIPH, was diagnosed on the basis of increased size and number of islet cells (Fig. 3).

DISCUSSION

The differential diagnosis of hypoglycemia is extensive. Appropriate workup will usually elucidate the cause of symptoms. Although rare, one must consider NIPH, particularly
NIPH is not associated with the same KATP channel gene mutations as those observed in nesidioblastosis. However, patch clamp experiments of beta cells from a patient with NIPH demonstrated a state of constant depolarization even at low glucose levels, suggesting a role of KATP channel physiology in the pathogenesis of NIPH.

Differentiating NIPH from insulinoma preoperatively remains difficult. Negative imaging studies have been included as a feature of NIPH, although patients may still have microinsulinomas too small to be detected on radiology. Our patient did have a lesion seen on CT, which was palpable at the time of surgery. Gupta et al. [8] describe a similar case where insulinoma was suspected based on clinical picture, preoperative imaging and intraoperative ultrasound but final pathology showed NIPH; by contrast, in their case imaging demonstrated multiple lesions, none of which were grossly detectable intraoperatively.

The majority of patients with NIPH will be controlled by distal pancreatectomy. Early studies suggested a 70% success rate in achieving normoglycemia for NIPH with <10% risk of diabetes mellitus when 60–85% of the pancreas were resected [9]. Gradient-guided distal pancreatectomy following selective arterial calcium stimulation is another technique to aid in extent of resection [10]. Despite amelioration of symptoms and hypoglycemia following pancreatic resection, recurrence has been an issue. A notable study from the Mayo Clinic demonstrated improved quality of life following pancreatic resection; symptom recurrence, when present, was usually less severe and debilitating than previous [3]. Diazoxide can be used when hypoglycemia persists postoperatively. Verapamil and octreotide may be added in cases of persistent hypoglycemia [2]. Ultimately, subtotal or even total pancreatectomy may be pursued if necessary.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING

A.M.J.S. is supported through a Canada Research Chair in Transplantation Surgery and Regenerative Medicine from the Canadian Research Council. He also receives funding from Alberta Innovates Healthcare Solutions, a Canadian Clinical Trial Network grant from the Juvenile Diabetes Research Foundation. This work was additionally supported through the Diabetes Research Institute Foundation of Canada (DRIFCan).

REFERENCES

1. Chiruvella A, Kooby DA. Surgical management of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 2016;25:401–21.
2. Habri AL, Bayard C. Nesidioblastosis associated with hyperinsulinemic hypoglycemia in adults: review of the literature. Eur J Intern Med 2004;15:407–10.
3. Vanderveen KA, Grant CS, Thompson GB, Farley DR, Richards ML, Vella A, et al. Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreaticogenic hypoglycemia from diffuse islet cell disease. Surgery 2010;148:1237–45; discussion 45-6.
4. Ritz P, Vaurs C, Barigou M, Hanaire H. Hypoglycaemia after gastric bypass: mechanisms and treatment. Diabetes Obes Metab 2016;18:217–23.
5. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353:249–54.
6. Ouyang D, Dhall D, Yu R. Pathologic pancreatic endocrine cell hyperplasia. World J Gastroenterol 2011;17:137–43.
7. Branstrom R, Berglund E, Curman P, Forsberg L, Hoog A, Grimmelius L, et al. Electrical short-circuit in beta-cells from a patient with non-insulinoma pancreaticogenic hypoglycemic syndrome (NIPHS): a case report. J Med Case Rep 2010;4:315.
8. Gupta RA, Patel RP, Nagral S. Adult onset nesidioblastosis treated by subtotal pancreatectomy. JOP 2013;14:286–8.
9. Witteles RM, Straus IF, Sugg SL, Koka MR, Costa EA, Kaplan EL. Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma. Arch Surg 2001;136:656–63.

10. Thompson SM, Vella A, Thompson GB, Rumilla KM, Service FJ, Grant CS, et al. Selective arterial calcium stimulation with hepatic venous sampling differentiates insulinoma from nesidioblastosis. J Clin Endocrinol Metab 2015;100:4189–97.